论文部分内容阅读
中晚期卵巢癌不良疗效的主要原因之一是机体对化疗产生耐药。本文采用流式细胞分析免疫技术，对近6年卵巢癌复发38例的肿瘤组织、外周血、腹水的细胞进行多药耐药基因（MDR1）检测、分析。结果提示：肿瘤多药耐药基因（MDR1）表达产物P－糖蛋白（P（107））的异常增加，产生生物作用，致使患者耐药、治疗失败。在复发肿瘤组织及外周血细胞MDR1阳性表达分别占81％、78％．P（170）含量在4％～11．94％。文章讨论了P（107）致耐药的作用机理并指出MDR1异常表达虽不是耐药的唯一机制，但与肿瘤的复发相关。
One of the main reasons for the poor efficacy of advanced ovarian cancer is the body’s resistance to chemotherapy. In this paper, flow cytometry analysis of immune technology, nearly 6 years of ovarian cancer recurrence in 38 cases of tumor tissue, peripheral blood, ascites cells were multidrug resistance gene (MDR1) detection and analysis. The results suggest that the abnormal increase of P-glycoprotein (P (107)), a product of multidrug resistance gene (MDR1), has a biological effect, resulting in drug resistance and failure of treatment. MDR1 positive expression in recurrent tumor tissue and peripheral blood cells accounted for 81%, 78%. P (170) content of 4% to 11.94%. The article discusses the mechanism of drug resistance induced by P (107) and points out that although the abnormal expression of MDR1 is not the only mechanism of drug resistance, it is related to tumor recurrence.